No Data
No Data
Express News | JPMorgan Chase & Co's Long Position in H-Shares of WuXi AppTec Increases to 6.28% on May 2 From 5.76% - HKEX
WUXI APPTEC CO LTD UNSPON ADS EACH REP 1 ORD SHS To Go Ex-Dividend On May 9th, 2025 With 0.13453 USD Dividend Per Share And 0.04796 USD Special Dividend Per Share
Trending Industry Today: BEIGENE Leads Losses In Biotechnology Stocks
Hong Kong stocks movement | Trump predicts pharmaceutical tariffs, with pharmaceutical stocks generally declining. HBM HOLDINGS-B (02142) fell more than 7%.
Pharmaceutical stocks generally declined in the morning session. As of the time of writing, HBM HOLDINGS-B (02142) fell 7.06% to 8.04 Hong Kong dollars; JUNSHI BIO (01877) fell 6.38% to 14.98 Hong Kong dollars; REMEGEN (09995) fell 6.48% to 38.25 Hong Kong dollars.
Trump wants to impose tariffs on Pharmaceuticals: Pharmaceutical companies are busy stockpiling, and the import volume in the USA surged in March.
① The volume of Pharmaceutical imports in the USA surged in March, as pharmaceutical companies stockpiled products in anticipation of potential tariffs; ② A report released by the US Department of Commerce on Tuesday showed that the total value of Pharmaceutical imports in March exceeded 50 billion USD, equivalent to 20% of the total Pharmaceutical imports for the entire year of 2024.
CICC: Lowers the Target Price of WUXI APPTEC to HKD 78.8, maintains "outperforming the Industry" rating.
CICC released a Research Report stating that WUXI APPTEC (02359) will have a revenue increase of 21% year-on-year in the first quarter of 2025 to 9.65 billion RMB; the income from continuous Business operations will increase by 23.1% to 9.39 billion; net profit will increase by 89.1% to 3.672 billion RMB; adjusted non-IFRS net profit will increase by 40% to 2.68 billion RMB; the backlog of Orders for continuous Business operations will increase by 47.1% to 52.33 billion RMB, slightly exceeding expectations. CICC stated that the growth in Orders is strong, the Tides Business continues to expand, and maintains an 'Outperform the Industry' rating, but due to a systematic adjustment in the Industry, the Target Price for H shares has been lowered by 10.5% to 78.8 HKD.